交易 Mersana Therapeutics, Inc. - MRSN CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
价差 | - | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.025457% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | 0.003235% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
Mersana Therapeutics Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平仓 | Change | Change (%) | 開倉 | High | Low |
---|
Mersana Therapeutics, Inc. Events
时间(协调世界时) (UTC) | 国家/地区 | 事件 |
---|---|---|
Wednesday, June 7, 2023 | ||
时间(协调世界时) (UTC) 13:00 | 国家/地区 US
| 事件 Mersana Therapeutics Inc at Jefferies Healthcare Conference Mersana Therapeutics Inc at Jefferies Healthcare ConferenceForecast -Previous - |
Thursday, June 8, 2023 | ||
时间(协调世界时) (UTC) 14:00 | 国家/地区 US
| 事件 Mersana Therapeutics Inc Annual Shareholders Meeting Mersana Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
Friday, June 9, 2023 | ||
时间(协调世界时) (UTC) 13:00 | 国家/地区 US
| 事件 Mersana Therapeutics Inc Annual Shareholders Meeting Mersana Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
Monday, August 7, 2023 | ||
时间(协调世界时) (UTC) 20:00 | 国家/地区 US
| 事件 Q2 2023 Mersana Therapeutics Inc Earnings Release Q2 2023 Mersana Therapeutics Inc Earnings ReleaseForecast -Previous - |
Monday, November 6, 2023 | ||
时间(协调世界时) (UTC) 13:30 | 国家/地区 US
| 事件 Q3 2023 Mersana Therapeutics Inc Earnings Release Q3 2023 Mersana Therapeutics Inc Earnings ReleaseForecast -Previous - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
总收入 | 26.581 | 0.043 | 0.828 | 42.123 | 10.594 |
收入 | 26.581 | 0.043 | 0.828 | 42.123 | 10.594 |
总营业费用 | 230.348 | 168.901 | 88.938 | 72.323 | 76.249 |
销售/一般/行政费用,总计 | 56.963 | 36.888 | 21.902 | 17.283 | 16.334 |
研究与开发 | 173.385 | 132.013 | 67.036 | 55.04 | 59.915 |
Depreciation / Amortization | |||||
营业收入 | -203.767 | -168.858 | -88.11 | -30.2 | -65.655 |
利息收入(费用),非经营净值 | -0.445 | -1.202 | 0.065 | 1.992 | 1.398 |
其他,净值 | |||||
税前净收入 | -204.212 | -170.06 | -88.045 | -28.208 | -64.257 |
税后净收入 | -204.212 | -170.06 | -88.045 | -28.208 | -64.257 |
未计算非常项目前的净收益 | -204.212 | -170.06 | -88.045 | -28.208 | -64.257 |
净收入 | -204.212 | -170.06 | -88.045 | -28.208 | -64.257 |
普通股股东可获收益 (不含非经常性项目) | -204.212 | -170.06 | -88.045 | -28.208 | -64.257 |
普通股股东可获收益 (含非經常性項目) | -204.212 | -170.06 | -88.045 | -28.208 | -64.257 |
摊薄净收入 | -204.212 | -170.06 | -88.045 | -28.208 | -64.257 |
摊薄后加权平均股 | 93.6542 | 70.5809 | 61.4852 | 43.4921 | 23.0322 |
扣除特别项目的每股摊薄盈利 | -2.18049 | -2.40943 | -1.43197 | -0.64858 | -2.78987 |
Dividends per Share - Common Stock Primary Issue | |||||
每股正常摊薄盈利 | -2.18049 | -2.40943 | -1.43197 | -0.64858 | -2.78987 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
总收入 | 7.802 | 14.688 | 5.573 | 4.284 | 2.036 |
收入 | 7.802 | 14.688 | 5.573 | 4.284 | 2.036 |
总营业费用 | 65.603 | 60.514 | 65.212 | 56.034 | 48.588 |
销售/一般/行政费用,总计 | 18.328 | 14.805 | 14.573 | 14.803 | 12.782 |
研究与开发 | 47.275 | 45.709 | 50.639 | 41.231 | 35.806 |
营业收入 | -57.801 | -45.826 | -59.639 | -51.75 | -46.552 |
利息收入(费用),非经营净值 | 1.638 | 0.902 | -0.172 | -0.469 | -0.706 |
税前净收入 | -56.163 | -44.924 | -59.811 | -52.219 | -47.258 |
税后净收入 | -56.163 | -44.924 | -59.811 | -52.219 | -47.258 |
未计算非常项目前的净收益 | -56.163 | -44.924 | -59.811 | -52.219 | -47.258 |
净收入 | -56.163 | -44.924 | -59.811 | -52.219 | -47.258 |
普通股股东可获收益 (不含非经常性项目) | -56.163 | -44.924 | -59.811 | -52.219 | -47.258 |
普通股股东可获收益 (含非經常性項目) | -56.163 | -44.924 | -59.811 | -52.219 | -47.258 |
摊薄净收入 | -56.163 | -44.924 | -59.811 | -52.219 | -47.258 |
摊薄后加权平均股 | 107.515 | 101.095 | 97.6419 | 95.7568 | 79.9286 |
扣除特别项目的每股摊薄盈利 | -0.52238 | -0.44437 | -0.61255 | -0.54533 | -0.59125 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常摊薄盈利 | -0.52238 | -0.44437 | -0.61255 | -0.54533 | -0.59125 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流动资产总额 | 319.219 | 188.898 | 258.58 | 101.326 | 74.305 |
现金和短期投资 | 280.712 | 177.947 | 255.094 | 99.79 | 70.131 |
现金等价物 | 128.885 | 177.947 | 255.094 | 62.351 | 59.634 |
应收账款总额,净额 | 30 | 0 | 0.459 | ||
Accounts Receivable - Trade, Net | 30 | 0 | 0.459 | ||
Prepaid Expenses | 8.507 | 10.951 | 3.486 | 1.536 | 3.715 |
Total Assets | 334.34 | 206.111 | 273.399 | 107.541 | 78.502 |
Property/Plant/Equipment, Total - Net | 14.46 | 14.857 | 12.666 | 4.762 | 2.694 |
Property/Plant/Equipment, Total - Gross | 22.202 | 22.539 | 20.301 | 11.971 | 9.055 |
Accumulated Depreciation, Total | -7.742 | -7.682 | -7.635 | -7.209 | -6.361 |
Other Long Term Assets, Total | 0.661 | 2.356 | 2.153 | 1.453 | 1.503 |
Total Current Liabilities | 91.533 | 47.523 | 30.003 | 24.07 | 69.425 |
Accounts Payable | 13.951 | 12.321 | 8.34 | 7.296 | 10.727 |
Accrued Expenses | 45.982 | 31.019 | 17.583 | 11.205 | 12.375 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 31.36 | 3.944 | 3.987 | 4.815 | 46.323 |
Total Liabilities | 242.283 | 84.37 | 45.312 | 29.223 | 69.707 |
Total Long Term Debt | 25.132 | 25.075 | 5.151 | 4.476 | 0 |
Other Liabilities, Total | 125.618 | 11.772 | 10.158 | 0.677 | 0.282 |
Total Equity | 92.057 | 121.741 | 228.087 | 78.318 | 8.795 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.011 | 0.007 | 0.007 | 0.005 | 0.003 |
Additional Paid-In Capital | 746.889 | 572.213 | 508.499 | 270.662 | 172.966 |
Retained Earnings (Accumulated Deficit) | -654.691 | -450.479 | -280.419 | -192.374 | -164.166 |
Total Liabilities & Shareholders’ Equity | 334.34 | 206.111 | 273.399 | 107.541 | 78.502 |
Total Common Shares Outstanding | 105.145 | 73.7091 | 68.8413 | 45.388 | 23.2345 |
短期投资 | 151.827 | 0 | 37.439 | 10.497 | |
Long Term Investments | |||||
Other Equity, Total | -0.152 | 0 | 0.025 | -0.008 | |
Current Port. of LT Debt/Capital Leases | 0.24 | 0.239 | 0.093 | 0.754 | |
Long Term Debt | 24.929 | 24.626 | 4.977 | 4.201 | |
Capital Lease Obligations | 0.203 | 0.449 | 0.174 | 0.275 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
流动资产总额 | 281.807 | 319.219 | 300.037 | 237.079 | 241.47 |
现金和短期投资 | 273.919 | 280.712 | 290.126 | 225.128 | 230.057 |
现金等价物 | 122.825 | 128.885 | 184.082 | 135.338 | 230.057 |
Prepaid Expenses | 7.888 | 8.507 | 9.911 | 11.951 | 11.413 |
Total Assets | 296.195 | 334.34 | 314.85 | 252.351 | 258.267 |
Property/Plant/Equipment, Total - Net | 13.8 | 14.46 | 14.197 | 14.548 | 14.55 |
Other Long Term Assets, Total | 0.588 | 0.661 | 0.616 | 0.724 | 2.247 |
Total Current Liabilities | 83.402 | 91.533 | 88.794 | 71.47 | 56.463 |
Accounts Payable | 18.156 | 13.951 | 13.732 | 8.158 | 9.775 |
Accrued Expenses | 35.492 | 45.982 | 43.901 | 36.848 | 29.879 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 29.754 | 31.6 | 31.161 | 26.464 | 16.809 |
Total Liabilities | 231.901 | 242.283 | 224.621 | 118.317 | 117.741 |
Total Long Term Debt | 25.004 | 24.929 | 24.853 | 24.777 | 24.702 |
Long Term Debt | 25.004 | 24.929 | 24.853 | 24.777 | 24.702 |
Other Liabilities, Total | 123.495 | 125.821 | 110.974 | 22.07 | 36.576 |
Total Equity | 64.294 | 92.057 | 90.229 | 134.034 | 140.526 |
Common Stock | 0.011 | 0.011 | 0.01 | 0.01 | 0.009 |
Additional Paid-In Capital | 775.125 | 746.889 | 700.217 | 684.106 | 638.254 |
Retained Earnings (Accumulated Deficit) | -710.854 | -654.691 | -609.767 | -549.956 | -497.737 |
Other Equity, Total | 0.012 | -0.152 | -0.231 | -0.126 | |
Total Liabilities & Shareholders’ Equity | 296.195 | 334.34 | 314.85 | 252.351 | 258.267 |
Total Common Shares Outstanding | 109.061 | 105.145 | 98.5826 | 97.1664 | 87.0731 |
Property/Plant/Equipment, Total - Gross | 22.202 | ||||
Current Port. of LT Debt/Capital Leases | |||||
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Accumulated Depreciation, Total | -7.742 | ||||
Capital Lease Obligations | |||||
短期投资 | 151.094 | 151.827 | 106.044 | 89.79 | |
应收账款总额,净额 | 0 | 30 | |||
Accounts Receivable - Trade, Net | 0 | 30 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | -204.212 | -170.06 | -88.045 | -28.208 | -64.257 |
经营活动产生的现金 | -49.363 | -139.988 | -74.696 | -67.744 | -55.216 |
经营活动产生的现金 | 0.927 | 0.855 | 1.01 | 1.245 | 1.257 |
非现金物品 | 20.823 | 19.132 | 7.234 | 4.753 | 3.718 |
营运资金的变化 | 133.099 | 10.085 | 5.105 | -45.534 | 4.066 |
投资活动产生的现金 | -152.716 | -0.648 | 37.027 | -27.293 | 87.195 |
资本支出 | -2.197 | -0.648 | -0.473 | -0.605 | -1.37 |
其他投资现金流量项目,总计 | -150.519 | 0 | 37.5 | -26.688 | 88.565 |
融资活动产生的现金 | 153.017 | 63.646 | 230.412 | 97.704 | 1.064 |
股票的发行(报废),净额 | 153.289 | 2.477 | 167.689 | 92.826 | 1.064 |
现金净变化 | -49.062 | -76.99 | 192.743 | 2.667 | 33.043 |
已付现金利息 | 2.463 | 0.429 | 0.234 | 0.132 | |
债务的发行(退还),净额 | -0.272 | 61.428 | 62.723 | 4.878 | |
融资现金流项目 | 0 | -0.259 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -56.163 | -204.212 | -159.288 | -99.477 | -47.258 |
Cash From Operating Activities | -29.005 | -49.363 | 1.866 | -52.731 | -7.955 |
Cash From Operating Activities | 0.319 | 0.927 | 0.645 | 0.432 | 0.205 |
Non-Cash Items | 5.148 | 20.823 | 16.386 | 11.11 | 5.679 |
Cash Interest Paid | 0.791 | 2.463 | 1.746 | 1.1 | 0.531 |
Changes in Working Capital | 21.691 | 133.099 | 144.123 | 35.204 | 33.419 |
Cash From Investing Activities | 1.396 | -152.716 | -107.29 | -90.799 | -0.329 |
Capital Expenditures | -0.911 | -2.197 | -1.412 | -0.986 | -0.329 |
Other Investing Cash Flow Items, Total | 2.307 | -150.519 | -105.878 | -89.813 | |
Cash From Financing Activities | 21.549 | 153.017 | 111.559 | 100.921 | 60.394 |
Financing Cash Flow Items | -0.15 | 0 | 0 | 0 | 0 |
Issuance (Retirement) of Stock, Net | 21.764 | 153.289 | 111.766 | 101.063 | 60.47 |
Issuance (Retirement) of Debt, Net | -0.065 | -0.272 | -0.207 | -0.142 | -0.076 |
Net Change in Cash | -6.06 | -49.062 | 6.135 | -42.609 | 52.11 |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
OrbiMed Advisors, LLC | Investment Advisor/Hedge Fund | 7.8781 | 9011437 | 0 | 2023-03-31 | LOW |
Bain Capital Life Sciences Investors, LLC | Investment Advisor | 7.5741 | 8663673 | 0 | 2023-03-31 | LOW |
Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 6.6005 | 7550000 | 0 | 2023-03-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.6058 | 6412222 | 556161 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.5956 | 6400549 | 15793 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.0377 | 4618576 | 189452 | 2023-03-31 | LOW |
Bellevue Asset Management AG | Investment Advisor | 3.7589 | 4299619 | 17019 | 2023-03-31 | LOW |
Rock Springs Capital Management LP | Hedge Fund | 3.5877 | 4103803 | 0 | 2023-03-31 | LOW |
Sarissa Capital Management, L.P. | Hedge Fund | 3.3221 | 3800000 | -197010 | 2023-03-31 | |
Avidity Partners Management LP | Hedge Fund | 3.0015 | 3433233 | 3433233 | 2023-03-31 | LOW |
Braidwell LP | Hedge Fund | 2.9338 | 3355805 | 1493105 | 2023-03-31 | HIGH |
Candriam Belgium S.A. | Investment Advisor/Hedge Fund | 2.5902 | 2962848 | 270000 | 2023-03-31 | LOW |
Candriam Luxembourg S.A. | Investment Advisor | 2.4788 | 2835409 | 0 | 2023-04-30 | HIGH |
Marshall Wace LLP | Investment Advisor/Hedge Fund | 2.1827 | 2496710 | -27274 | 2023-03-31 | HIGH |
Invus Public Equities Advisors, LLC | Investment Advisor | 1.9371 | 2215788 | 15788 | 2023-03-31 | LOW |
Baker Bros. Advisors LP | Hedge Fund | 1.6489 | 1886115 | 1886115 | 2023-03-31 | LOW |
D. E. Shaw & Co., L.P. | Hedge Fund | 1.579 | 1806099 | -529840 | 2023-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.5726 | 1798847 | 91377 | 2023-03-31 | LOW |
Goldman Sachs Asset Management, L.P. | Investment Advisor | 1.5083 | 1725328 | 101999 | 2023-03-31 | LOW |
Millennium Management LLC | Hedge Fund | 1.1025 | 1261054 | -2402473 | 2023-03-31 | HIGH |
交易计算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Mersana Therapeutics, Inc. Company profile
关于 Mersana Therapeutics Inc.
Mersana Therapeutics, Inc.是一家处于临床阶段的生物制药公司。 该公司专注于开发抗体药物结合物(ADCs)。 公司的平台包括Dolaflexin和Dolasynthen。 其候选产品包括upifitamab rilsodotin(UpRi,XMT-1536)和XMT-1592。 公司的早期项目包括针对B7-H4的Dolasynthen ADC,XMT-1660,以及利用Immunosynthen平台的候选产品。 UpRi是一种利用公司Dolaflexin平台的ADC,针对NaPi2b,这是一种在卵巢癌和非小细胞肺癌(NSCLC)腺癌中广泛表达的抗原。 XMT-1592采用公司的Dolasynthen平台,靶向NaPi2b。
Industry: | Bio Therapeutic Drugs |
840 Memorial Dr
CAMBRIDGE
MASSACHUSETTS 02139
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球535,000万多名交易者的一份子,选择利用Capital.com进行交易吧。